欢迎访问《现代生物医学进展》编辑部！

v目的：探讨伊班膦酸钠注射液联合钙尔奇 D 片治疗老年性骨质疏松症的疗效及对患者血尿常规、肝肾功能及心电图的影响。方法：选择我院收治的 72 例老年骨质疏松症患者，采用随机数字表法将其分为观察组和对照组各 36 例，观察组给予伊班膦酸钠注射液联合钙尔奇 D 片进行治疗，对照组仅给予钙尔奇 D 片进行治疗，治疗时间为 12 个月，在治疗前，治疗后 6 个月及治疗后 12 个月时对比两组治疗效果及临床不良反应发生情况，并对两组患者的血尿常规、肝肾功能及心电图进行对比检查。结果：观察组在治疗 6 个月时 BALP 和 TRAP-5b 分别为（ 1 0.96± 0.93）ug/L、（ 3.71± 0.72）U/L，较治疗前和对照组均明显下降，比较差异均有统计学意义（ P<0.05）；观察组在治疗 12 个月时 BALP 和 TRAP-5b 分别为（ 10.91± 0.81）ug/L、（ 3.73± 0.65）U/L，较治疗前和对照组亦显著下降，比较差异均有统计学意义（ P<0.05）；对照组在治疗后 6 个月及 12 个月时，各检测指标统计值与治疗前比较，变化不大，比较差异均无统计学意义（ P>0.05）；两种患者在治疗前、 6 个月、 12 个月时血尿常规、肝肾功能及心电图之间无统计学差异（ P>0.05）；两组患者中均无明显严重的不良反应发生，不良反应发生情况比较差异无统计学意义（ P>0.05）。结论：临床中联合应用伊班膦酸钠注射液和钙尔奇 D 片对老年性骨质疏松症进行治疗，可获得较为满意疗效，且对患者血尿常规、肝肾功能及心电图影响较小，不良反应发生率较低，病人耐受度较好，故值得在临床中应用。

英文摘要:

Objective:To investigate ibandronate injection combined with Caltrate D tablets in the treatment of senile osteoporosis efficacy and its influence on patients’ urine routine, liver and kidney function and ECG.Methods:72 elderly patients with osteoporosis admitted to hospital were randomly divided into the two- serial- method group and the control group, with 36 cases in each group, the observation group was given ibandronate injection combined with Caltrate D slices treatment, while the control group was given Caltrate D tablets for treatment, and the treatment period was 12 months. At time of before treatment, 6 -month and 12 -month post treatment, the therapeutic effect and clinical adverse reaction were compared, and the urine routine, liver and kidney function and ECG of the two groups of patients were also compared.Results:The BALP and TRAP-5b in study group 6 months post treatment were (1 0.96± 0.93) ug/L, (3.71± 0.72) U/L respectively, compared with before the treatment and the control groups, significant decrease was observed (P<0.05); observation group, in the 12th month of treatment, BALP and TRAP-5b were (1 0.91 ± 0.81) ug/L and (3.73 ± 0.65) U/L respectively, there was also significantly decrease when compared with before treatment and control group, and the difference was statistically significant (P<0.05); after 6 months of treatment and 1 2 months, no statistical difference on the value of each detection or treatment index was found in the control group during the treatment period (P>0.05); There was no urine routine, liver and kidney function and ECG -related statistically significant difference in two groups of patients before treatment, or after 6 months and 12 months of treatment, (P>0.05); patients in both groups had no significantly serious adverse events, and the incidence of adverse reactions was not significant (P>0.05).Conclusion:The combination of clinical ibandronate injections and Caltrate D tablets on senile osteoporosis treatment, obtains more satisfactory results and the urine routine, liver and kidney function and electrocardiogram were less affected. Since the incidence of adverse reactions was lower, and the patients could tolerate well, it is worth clinical application.

View Full Text View/Add Comment Download reader